Plain-English translation of ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether human umbilical cord mesenchymal stem cells () can help repair kidneys that have been damaged by diabetes. Researchers believe these stem cells may be able to reduce kidney inflammation, protect kidney cells from dying, and help regenerate new kidney tissue. The medication is given as an injection directly to the damaged kidney area.
Diabetic kidney disease is a serious complication that affects up to 40% of people with long-standing diabetes, and current medications can only slow the damage but cannot reverse it. This trial exists because this treatment may offer a new way to actually repair kidney tissue and prevent kidney failure.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital for a stem cell injection procedure. The study will carefully monitor your kidney function and overall health over time through follow-up visits and blood tests. The researchers will track whether the treatment helps slow or reverse your kidney damage and compare your results with a control group to understand how well this new treatment works.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China